تعداد نشریات | 20 |
تعداد شمارهها | 1,053 |
تعداد مقالات | 9,692 |
تعداد مشاهده مقاله | 12,902,620 |
تعداد دریافت فایل اصل مقاله | 6,147,542 |
Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report | ||
Iranian Journal of Immunology | ||
مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 02 آبان 1402 اصل مقاله (1.66 M) | ||
نوع مقاله: Case Report | ||
شناسه دیجیتال (DOI): 10.22034/iji.2023.99254.2629 | ||
نویسندگان | ||
Miao Zhu1، 2؛ Jun Zhang2؛ Qingqing Shi2؛ Xing Sun2؛ Haibo Wang1؛ Mei Sun2؛ Yanqing Liu* 1 | ||
1The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China. | ||
2Clinical Medical College, Yangzhou University, Yangzhou 225001, China. | ||
چکیده | ||
Hemophagocytic lymphohistiocytosis (HLH) is a fatal clinical syndrome. The most common cause of secondary HLH is Epstein-Barr virus (EBV) infection. EBV-HLH is a common clinical disease with high mortality, easy relapse, and poor prognosis. Therefore, treating EBV-HLH with T and B lymphocyte involvement is challenging, and selecting an appropriate treatment regimen is critical. Moreover, research on how to evaluate the recurrence index after remission is scarce. In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes. | ||
کلیدواژهها | ||
CD20 Monoclonal Antibody؛ Epstein-Barr Virus؛ Hemophagocytic Lymphohistiocytosis؛ Programmed Cell Death Protein-1؛ Salvage Therapy | ||
آمار تعداد مشاهده مقاله: 210 تعداد دریافت فایل اصل مقاله: 75 |